Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma

Final results of an intergroup trial

Patrick Loehrer, Kyungmann Kim, Seena C. Aisner, Robert Livingston, Lawrence Einhorn, David Johnson, Ronald Blum

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to evaluate the impact of cisplatin, doxorubicin, and cyclophosphamide (PAC) in patients with advanced thymoma with respect to response rate, duration of remission, and overall survival. Patients and Methods: Assessable patients with thymoma (n = 29) or thymic carcinoma (n = 1) with metastatic or locally progressive recurrent disease following radiotherapy were treated with intravenous cisplatin (50 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) with normal saline hydration. Courses were repeated every 3 weeks for a maximum of eight cycles of therapy. Results: Toxicity, which was primarily hematologic, was mild, with only one patient developing a fever associated with neutropenia. Three complete responses (CRs) and 12 partial responses (PRs) were observed (CR + PR rate, 50%; 95% confidence interval, 31.3% to 68.7%). Ten patients had stable disease. The median duration of response was 11.8 months (range, 0.9 to 70.5+), the time to treatment failure 18.4 months (range, 0.8 to 91.9+), and median survival time 37.7 months (range, 2 to 91.9+). Conclusion: This trial demonstrates that objective response rates and prolonged survival can be achieved in patients with advanced thymoma.

Original languageEnglish
Pages (from-to)1164-1168
Number of pages5
JournalJournal of Clinical Oncology
Volume12
Issue number6
StatePublished - Jun 1994

Fingerprint

Thymoma
Doxorubicin
Cyclophosphamide
Cisplatin
Survival
Neutropenia
Treatment Failure
Fever
Radiotherapy
Survival Rate
Confidence Intervals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma : Final results of an intergroup trial. / Loehrer, Patrick; Kim, Kyungmann; Aisner, Seena C.; Livingston, Robert; Einhorn, Lawrence; Johnson, David; Blum, Ronald.

In: Journal of Clinical Oncology, Vol. 12, No. 6, 06.1994, p. 1164-1168.

Research output: Contribution to journalArticle

Loehrer, Patrick ; Kim, Kyungmann ; Aisner, Seena C. ; Livingston, Robert ; Einhorn, Lawrence ; Johnson, David ; Blum, Ronald. / Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma : Final results of an intergroup trial. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 6. pp. 1164-1168.
@article{324dcf35d5ef45c794d394134fb1ba48,
title = "Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial",
abstract = "Purpose: The purpose of this study was to evaluate the impact of cisplatin, doxorubicin, and cyclophosphamide (PAC) in patients with advanced thymoma with respect to response rate, duration of remission, and overall survival. Patients and Methods: Assessable patients with thymoma (n = 29) or thymic carcinoma (n = 1) with metastatic or locally progressive recurrent disease following radiotherapy were treated with intravenous cisplatin (50 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) with normal saline hydration. Courses were repeated every 3 weeks for a maximum of eight cycles of therapy. Results: Toxicity, which was primarily hematologic, was mild, with only one patient developing a fever associated with neutropenia. Three complete responses (CRs) and 12 partial responses (PRs) were observed (CR + PR rate, 50{\%}; 95{\%} confidence interval, 31.3{\%} to 68.7{\%}). Ten patients had stable disease. The median duration of response was 11.8 months (range, 0.9 to 70.5+), the time to treatment failure 18.4 months (range, 0.8 to 91.9+), and median survival time 37.7 months (range, 2 to 91.9+). Conclusion: This trial demonstrates that objective response rates and prolonged survival can be achieved in patients with advanced thymoma.",
author = "Patrick Loehrer and Kyungmann Kim and Aisner, {Seena C.} and Robert Livingston and Lawrence Einhorn and David Johnson and Ronald Blum",
year = "1994",
month = "6",
language = "English",
volume = "12",
pages = "1164--1168",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma

T2 - Final results of an intergroup trial

AU - Loehrer, Patrick

AU - Kim, Kyungmann

AU - Aisner, Seena C.

AU - Livingston, Robert

AU - Einhorn, Lawrence

AU - Johnson, David

AU - Blum, Ronald

PY - 1994/6

Y1 - 1994/6

N2 - Purpose: The purpose of this study was to evaluate the impact of cisplatin, doxorubicin, and cyclophosphamide (PAC) in patients with advanced thymoma with respect to response rate, duration of remission, and overall survival. Patients and Methods: Assessable patients with thymoma (n = 29) or thymic carcinoma (n = 1) with metastatic or locally progressive recurrent disease following radiotherapy were treated with intravenous cisplatin (50 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) with normal saline hydration. Courses were repeated every 3 weeks for a maximum of eight cycles of therapy. Results: Toxicity, which was primarily hematologic, was mild, with only one patient developing a fever associated with neutropenia. Three complete responses (CRs) and 12 partial responses (PRs) were observed (CR + PR rate, 50%; 95% confidence interval, 31.3% to 68.7%). Ten patients had stable disease. The median duration of response was 11.8 months (range, 0.9 to 70.5+), the time to treatment failure 18.4 months (range, 0.8 to 91.9+), and median survival time 37.7 months (range, 2 to 91.9+). Conclusion: This trial demonstrates that objective response rates and prolonged survival can be achieved in patients with advanced thymoma.

AB - Purpose: The purpose of this study was to evaluate the impact of cisplatin, doxorubicin, and cyclophosphamide (PAC) in patients with advanced thymoma with respect to response rate, duration of remission, and overall survival. Patients and Methods: Assessable patients with thymoma (n = 29) or thymic carcinoma (n = 1) with metastatic or locally progressive recurrent disease following radiotherapy were treated with intravenous cisplatin (50 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) with normal saline hydration. Courses were repeated every 3 weeks for a maximum of eight cycles of therapy. Results: Toxicity, which was primarily hematologic, was mild, with only one patient developing a fever associated with neutropenia. Three complete responses (CRs) and 12 partial responses (PRs) were observed (CR + PR rate, 50%; 95% confidence interval, 31.3% to 68.7%). Ten patients had stable disease. The median duration of response was 11.8 months (range, 0.9 to 70.5+), the time to treatment failure 18.4 months (range, 0.8 to 91.9+), and median survival time 37.7 months (range, 2 to 91.9+). Conclusion: This trial demonstrates that objective response rates and prolonged survival can be achieved in patients with advanced thymoma.

UR - http://www.scopus.com/inward/record.url?scp=0028282439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028282439&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1164

EP - 1168

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -